Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Total Non-Current Liabilities (2016 - 2024)

Voyager Therapeutics (VYGR) has disclosed Total Non-Current Liabilities for 10 consecutive years, with $56.4 million as the latest value for Q3 2024.

  • Quarterly Total Non-Current Liabilities fell 43.36% to $56.4 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $56.4 million through Sep 2024, down 43.36% year-over-year, with the annual reading at $96.9 million for FY2023, 22.55% up from the prior year.
  • Total Non-Current Liabilities hit $56.4 million in Q3 2024 for Voyager Therapeutics, down from $59.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $211.8 million in Q1 2020 to a low of $56.3 million in Q3 2021.
  • Historically, Total Non-Current Liabilities has averaged $91.5 million across 5 years, with a median of $80.6 million in 2022.
  • Biggest five-year swings in Total Non-Current Liabilities: plummeted 72.44% in 2021 and later surged 88.68% in 2022.
  • Year by year, Total Non-Current Liabilities stood at $62.9 million in 2020, then fell by 5.83% to $59.2 million in 2021, then skyrocketed by 33.54% to $79.0 million in 2022, then increased by 22.55% to $96.9 million in 2023, then plummeted by 41.81% to $56.4 million in 2024.
  • Business Quant data shows Total Non-Current Liabilities for VYGR at $56.4 million in Q3 2024, $59.6 million in Q2 2024, and $85.7 million in Q1 2024.